CDT Highlights Sarborg's Solid-Form Patent Filing on a First-in-Class Respiratory Asset
CDT Equity highlighted a new solid-form patent filing by Sarborg Limited covering a first-in-class respiratory medicine addressing a treatment market estimated at more than $20 billion annually. CDT holds 1,290 Sarborg shares, or 22.7% of its issued capital, valued at roughly $161 million based on Sarborg's latest raise at $125,000 per share.
Key figures
- Cdt stake value
- $161 million
- Addressable market
- $20 billion annually
- Sarborg stake shares
- 1290
- Sarborg ownership pct
- 22.7%
- Sarborg last raise price per share
- $125,000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.